Pinart M, et al. – Experts identified and summarized existing multivariable prognostic models developed for predicting overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) in this systematic review. Medline and reference lists were systematically searched up to May 2018 to identify relevant studies, and included experimental and observational studies that reported on the development and/or internal validation of prognostic models for patients with mCRPC and were further externally validated or updated. A total of 12 studies including 8,750 patients aged 42-95 years met inclusion criteria. These models included 4-11 predictor variables, including hemoglobin, baseline PSA, alkaline phosphatase, performance status, and lactate dehydrogenase. Overall, due to methodological shortcomings and lack of external validation, most models were not suitable for clinical use. Similar discrimination power ranging from 0.62 to 0.73 was demonstrated by model performance after internal validation. An overall judgment of low risk of bias was obtained by two models.